A list of 2018 China’s Top 100 Pharmaceutical Companies was released on July 15. GPHL ranked first on the list, claiming the top spot for eight consecutive years now. Due to rapid yet sustainable development in recent years, GPHL’s total sales revenue has exceeded 100 billion yuan.

The list of 2018 China’s Top 100 Pharmaceutical Companies [Photo: MENET official wechat account]

The ranking was released by the China’s Top 100 Pharmaceutical Companies organizing committee led by MENET Institute (www.menet.com.cn), a medical industry news provider. Based on the data provided by MENET, medical enterprises were evaluated in terms of innovation and marketing.

GPHL is now both the largest pharmaceutical enterprise and the largest manufacturing base for Chinese patent medicine in China. GPHL ranked 165th on the 2018 list of China’s Top 500 Enterprises, a list seen as an indicator of performance amid a context of steady economic growth, and 68th on the China’s Top 500 Manufacturing Enterprises list in 2018.

Over the past years, GPHL has been promoting the idea of ‘Trendy TCM’, which aims to provide products targeting young people, using advanced manufacturing technology and accessible marketing methods. For GPHL, TCM is the feature of its industry, and ‘Trendy TCM’ is the impetus for further development.

GPHL’s subsidiary Guangzhou Baiyun Mountain and Hutchison Whampoa Ltd. (BMHW) is the largest Chinese patent medicine manufacturing enterprise in South China and possesses two of the top-selling TCM products in China, the Baiyunshan Banlangen Granule and Fufang Danshen Tablets. Shennong Caotang Museum, the first semi-enclosed garden-style TCM museum showcasing Lingnan medicine and medicinal plants, is also established by BMHW.

GPHL’s Wanglaoji won two second prizes of the National Science and Technology Progress Award in 2015 and 2017 for its species identification system of herb DNA bar code. On March 12, GPHL appointed 2013 Nobel Laureate in Medicine Randy Schekman as its chief scientist who is heading up the study and development of antineoplastic drugs.

A launch ceremony for the research of pseudo-ginseng’s Q-Marker (a marker for the quality of Chinese medicine).

GPHL also began construction of its R&D and marketing headquarters in Huangpu District and its medicine logistics park in Baiyun District in March 12 this year. Upon completion, the two projects will provide significant support for GPHL’s pursuit of building itself a world-class enterprise.

Author: Monica Liu

Editor: Chris